Xilio Development Inc

Stock Chart, Company Information, and Scan Results

$0.53(as of Mar 3, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Xilio Development Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$0.53
Ticker SymbolXLO
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees64
CountyUSA
Market Cap$39.7M
EBIDTA-42.2M
10-Day Moving Average0.55
P/E Ratio-1.30
20-Day Moving Average0.55
Forward P/E Ratio0.00
50-Day Moving Average0.61
Earnings per Share-0.61
200-Day Moving Average0.71
Profit Margin-85.42%
RSI37.13
Shares Outstanding73.5M
ATR0.04
52-Week High1.18
Volume234,856
52-Week Low0.50
Most Recent Support Level0.51
Book Value-8.1M
Most Recent Resistance Level0.56
P/B Ratio-9.40
Upper Keltner0.64
P/S Ratio2.39
Lower Keltner0.46
Debt-to-Equity Ratio0.64
Next Earnings DateUnknown
Cash Surplus47.4M
Next Ex-Dividend DateUnknown

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.